Skip to main content

Durvalumab with or without Tremelimumab in Treating Patients with Recurrent or Persistent Endometrial Cancer

Trial Status: Closed to Accrual

This randomized phase II trial studies how well durvalumab with or without tremelimumab works in treating patients with endometrial cancer that has come back after a period of time (recurrent) or remains despite treatment (persistent). Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving durvalumab with tremelimumab may work better than durvalumab alone in treating patients with recurrent or persistent endometrial cancer.

Inclusion Criteria

  • Subjects must have recurrent or persistent endometrial carcinoma (including: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, dedifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified [N.O.S.], mucinous adenocarcinoma, squamous cell carcinoma, and transitional cell carcinoma) or endometrial carcinosarcoma; histologic documentation of diagnosis of carcinoma is required; microsatellite instability (MSI)-high patients will be identified based on immunohistochemistry or MSI testing of archival tumor specimens by department of pathology or via known mutations found in mismatch repair genes via the Integrated Mutation Profiling of Actionable Cancer Targets (IMPACT) assay through Memorial Sloan Kettering Cancer Center (MSKCC) Institutional Review Board (IRB)# 12-245
  • All patients must have measurable disease; measurable disease is defined by RECIST (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
  • Patients must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST version 1.1; tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
  • Life expectancy of >= 12 weeks
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Resolution of (non-laboratory) adverse effects of recent surgery, radiotherapy, or chemotherapy to grade =< 1 prior to first study treatment (with the exception of alopecia or neuropathy)
  • Patients must have had one prior platinum-based chemotherapeutic regimen for management of endometrial carcinoma or carcinosarcoma; initial treatment may include chemotherapy, chemotherapy and radiation therapy, and/or consolidation/maintenance therapy; chemotherapy administered in conjunction with primary radiation as radio-sensitizer WILL be counted as a systemic chemotherapy regimen
  • Patients are allowed to receive, but are not required to receive, three additional cytotoxic regimen for management of recurrent or persistent disease; hormonal therapies will not count toward the prior regimen limit
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (> 1500 per mm^3) (obtained within 14 days prior to first treatment)
  • Platelet >= 100 x 10^9/L (> 100,000 per mm^3) (obtained within 14 days prior to first treatment)
  • Hemoglobin >= 9.0 g/dL (obtained within 14 days prior to first treatment)
  • Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN); (unless Gilbert's syndrome, for which bilirubin =< 3 x institutional upper limit of normal [ULN], without concurrent clinically significant liver disease) (obtained within 14 days prior to first treatment)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate-pyruvate transaminase [SGPT]) =< 3 x institutional upper limit of normal (ULN) unless liver metastases are present, in which case it must be =< 5 x ULN (obtained within 14 days prior to first treatment)
  • Serum creatinine =< 1.5 x institutional upper limit of normal (ULN) (obtained within 14 days prior to first treatment)
  • Female subjects must either be of non-reproductive potential (i.e., post-menopausal by history: >= 55 years old and no menses for >= 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry
  • Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
  • Patients must have been enrolled, or agree to consent to the companion genomic profiling study MSKCC IRB# 12-245; results must be available before starting treatment on protocol
  • Patients must have signed an approved informed consent and authorization permitting release of personal information

Exclusion Criteria

  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site); previous enrollment in the previous study
  • Participation in another clinical study with receipt of an investigational product during the last 4 weeks
  • Any previous treatment with a PD-1 or PD-L1 inhibitor, including durvalumab or any anti-CTLA4, including tremelimumab
  • History of another primary malignancy except for: * Malignancy treated with curative intent and with no known active disease >= 3 years before the first dose of study drug and of low potential risk for recurrence * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease * Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ) * Adequately treated stage 1 breast cancer
  • Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies) < 21 days prior to the first dose of study drug; receipt of the last dose of hormonal therapy within < 7 days prior to the first dose of study drug
  • Any prior radiation therapy must be discontinued at least four weeks prior to registration
  • At least 4 weeks must have elapsed since the patient underwent any major surgery (e.g., major: laparotomy, laparoscopy); there is no delay in treatment for minor procedures (e.g., central venous access catheter placement)
  • Patients should not be candidates for further surgical resection or definitive tumor-directed radiation therapy (XRT) based upon prior therapies and/or extent of disease at recurrence
  • Mean QT interval corrected for heart rate (QTc) >= 470 ms calculated from 3 electrocardiograms (ECGs)
  • Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or durvalumab and tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid; patients who have received acute, low dose, systemic immunosuppressant medications (e.g., dexamethasone for nausea or steroids as CT scan contrast premedication) may be enrolled
  • Any prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1
  • Active or prior documented autoimmune disease within the past 2 years * NOTE: subjects with vitiligo, Graves' disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded
  • Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
  • History of primary immunodeficiency
  • History and/or confirmed pneumonitis or interstitial lung disease
  • History of allogeneic organ transplant
  • History of hypersensitivity to durvalumab or any excipient
  • History of hypersensitivity to tremelimumab
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
  • Known history of previous clinical diagnosis of tuberculosis
  • History of leptomeningeal carcinomatosis
  • Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
  • Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
  • Subjects with uncontrolled seizures
  • Patients who are pregnant or breastfeeding or patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period
  • History of small or large bowel obstruction within 3 months of registration, including subjects with palliative gastric drainage catheters; subjects with palliative diverting ileostomy or colostomy are allowed if they have been symptom free for more than 3 months
  • Ongoing bowel perforation or presence of bowel fistula or abscess within 3 months of registration
  • Subjects with refractory ascites, defined as ascites needing drainage catheter or therapeutic paracentesis more often than every 4 weeks

New Jersey

Basking Ridge
Memorial Sloan Kettering Basking Ridge
Contact: Vicky Makker
Phone: 646-888-4215
Memorial Sloan Kettering Monmouth
Contact: Vicky Makker
Phone: 646-888-4215
Memorial Sloan Kettering Bergen
Contact: Vicky Makker
Phone: 646-888-4224

New York

Memorial Sloan Kettering Commack
Contact: Vicky Makker
Phone: 646-888-4215
New York
Memorial Sloan Kettering Cancer Center
Contact: Vicky Makker
Phone: 646-888-4215
Memorial Sloan Kettering Nassau
Contact: Vicky Makker
Phone: 646-888-4215
West Harrison
Memorial Sloan Kettering Westchester
Contact: Vicky Makker
Phone: 646-888-4215


I. Determine the effectiveness of each arm by measuring overall response rate (ORR = complete response [CR] + partial response [PR]) by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.

II. Determine progression free survival (PFS) rate in each arm at 24 weeks (+/- 1 week).


I. Overall response rate in each arm evaluated by immune-related Response Criteria in Solid Tumors (irRECIST) criteria.

II. Clinical benefit (CR + PR + stable disease [SD]) rate in each arm by 24 weeks +/- 7 days.

III. Duration of response in each arm.

IV. Determine the rate of immune-related adverse events (irAE).

V. Determine the rate of serious adverse events (SAE).

VI. Establish safety of each arm.


I. Determine the ability of the laboratory parameters to predict clinical benefit:

Ia. Archival tumor tissue PD-L1 expression immunohistochemistry (IHC).

Ib. Archival tumor tissue immune-related gene expression profiles.

Ic. Archival tumor tissue IHC.

Id. Peripheral blood immune phenotyping.

Ie. Peripheral blood gene expression profiling.

If. Peripheral blood T cell receptor repertoire.

Ig. Peripheral blood serologic responses.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive durvalumab intravenously (IV) over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive durvalumab over 60 minutes and tremelimumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 28 days, 90 days, and up to a minimum of 6 months.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Memorial Sloan Kettering Cancer Center

Principal Investigator
Vicky Makker

  • Primary ID 16-1491
  • Secondary IDs NCI-2017-00112
  • ID NCT03015129